WhiteLab Genomics, a genomic medicine company, closed a $26M Series B funding round led by AVP, with participation from new investors Yaday Health and Blast Club, as well as existing shareholders Omnes Capital and Debiopharm Innovation Fund. The funding will support the validation of WhiteLab's computational gene delivery designs in living systems and expand its portfolio of bio-assets. WhiteLab uses its ALFRED AI platform to design and optimize gene delivery components including AAVs, lipid nanoparticles, and synthetic promoters for gene therapy applications. The company focuses on building and licensing validated enabling technologies rather than developing complete medicines independently.
Company Information
Company
WhiteLab Genomics
About
WhiteLab Genomics is building a portfolio of AI-designed gene delivery assets and regulatory components for genomic medicines. The company uses its ALFRED platform to design and optimize delivery vectors (like AAVs and lipid nanoparticles) and synthetic promoters, which are then experimentally validated. WhiteLab owns and licenses these validated bio-assets while also partnering with biopharma companies for co-development programs. The company's work spans adeno-associated viruses, nonviral delivery technologies, and synthetic gene expression control elements.
Fundz sees it the moment WhiteLab Genomics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
